Pharma BD Deal Intelligence

AbTis Co., Ltd. / ProBio (GenScript Biotech)

2026 · Licensing/Option · Complete

ProBio, the CRDMO arm of GenScript Biotech, granted AbTis Co., Ltd. exclusive global rights to develop and commercialize a discovery-stage therapeutic antibody against an oncology target generated through ProBio's biologics discovery platform. AbTis, a South Korean subsidiary of Dong-A ST, will apply its proprietary AbClick site-specific conjugation platform to advance the antibody into a next-generation antibody-drug conjugate. The agreement provides ProBio an upfront payment, development and commercial milestones, and royalties on future sales; no financial terms were disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals